These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 22464314

  • 1. Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts.
    Walker KM, Pope J, participating members of the Scleroderma Clinical Trials Consortium (SCTC), Canadian Scleroderma Research Group (CSRG).
    Semin Arthritis Rheum; 2012 Aug; 42(1):42-55. PubMed ID: 22464314
    [Abstract] [Full Text] [Related]

  • 2. Treatment Algorithms for Systemic Sclerosis According to Experts.
    Fernández-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group.
    Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
    Pestaña-Fernández M, Rubio-Rivas M, Tolosa-Vilella C, Guillén-Del-Castillo A, Colunga-Argüelles D, Argibay A, Marí-Alfonso B, Marín-Ballvé A, Pla-Salas X, Chamorro AJ, Castro-Salomó A, Madroñero-Vuelta AB, Sánchez-García ME, Sáez-Comet L, González-Echávarri C, Ortego-Centeno N, Vargas-Hitos JA, Todolí-Parra JA, Trapiella-Martínez L, Lledó GM, Freire M, Fonollosa-Pla V, Simeón-Aznar CP, for RESCLE Investigators, Autoimmune Diseases Study Group (GEAS).
    Rheumatology (Oxford); 2021 Feb 01; 60(2):872-880. PubMed ID: 32844220
    [Abstract] [Full Text] [Related]

  • 6. Systemic sclerosis medications and risk of scleroderma renal crisis.
    Gordon SM, Hughes JB, Nee R, Stitt RS, Bailey WT, Little DJ, Edison JD, Olson SW.
    BMC Nephrol; 2019 Jul 25; 20(1):279. PubMed ID: 31345158
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].
    Sicińska J, Rudnicka L.
    Pol Merkur Lekarski; 2008 Aug 25; 25(146):196-200. PubMed ID: 18942347
    [Abstract] [Full Text] [Related]

  • 9. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
    Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A, Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators.
    Ann Rheum Dis; 2012 Feb 25; 71(2):249-52. PubMed ID: 21998119
    [Abstract] [Full Text] [Related]

  • 10. Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients.
    Moinzadeh P, Riemekasten G, Siegert E, Fierlbeck G, Henes J, Blank N, Melchers I, Mueller-Ladner U, Frerix M, Kreuter A, Tigges C, Lahner N, Susok L, Guenther C, Zeidler G, Pfeiffer C, Worm M, Karrer S, Aberer E, Bretterklieber A, Genth E, Simon JC, Distler JH, Hein R, Schneider M, Seitz CS, Herink C, Steinbrink K, Sárdy M, Varga R, Mensing H, Mensing C, Lehmann P, Neeck G, Fiehn C, Weber M, Goebeler M, Burkhardt H, Buslau M, Ahmadi-Simab K, Himsel A, Juche A, Koetter I, Kuhn A, Sticherling M, Hellmich M, Kuhr K, Krieg T, Ehrchen J, Sunderkoetter C, Hunzelmann N, German Network for Systemic Scleroderma.
    J Rheumatol; 2016 Jan 25; 43(1):66-74. PubMed ID: 26568599
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.
    Steen VD, Medsger TA.
    Arthritis Rheum; 1998 Sep 25; 41(9):1613-9. PubMed ID: 9751093
    [Abstract] [Full Text] [Related]

  • 14. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A, Abou-Raya S, Helmii M.
    J Rheumatol; 2008 Sep 25; 35(9):1801-8. PubMed ID: 18709692
    [Abstract] [Full Text] [Related]

  • 15. The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy.
    Strange G, Nash P.
    Int J Rheum Dis; 2009 Sep 25; 12(3):192-206. PubMed ID: 20374346
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
    Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y.
    Clin Dev Immunol; 2005 Sep 25; 12(3):165-73. PubMed ID: 16295521
    [Abstract] [Full Text] [Related]

  • 19. Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis.
    de Vries-Bouwstra JK, Allanore Y, Matucci-Cerinic M, Balbir-Gurman A.
    J Rheumatol; 2020 Feb 25; 47(2):249-254. PubMed ID: 31043545
    [Abstract] [Full Text] [Related]

  • 20. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
    Kuriyama S, Tomonari H, Ohtsuka Y, Ohkido I, Hosoya T.
    Nihon Jinzo Gakkai Shi; 2003 Feb 25; 45(4):367-71. PubMed ID: 12806973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.